Cardiac magnetic resonance imaging (MRI) measures of myocardial interstitial fibrosis (MIF) are elevated in heart failure with preserved ejection fraction (HFpEF) patients and associated with poor prognosis. Extracellular volume (ECV) is the most reproducible and best validated cardiac MRI measure of MIF. Sacubitril/valsartan reduces histological MIF in mice and levels of some extracellular matrix regulatory proteins in humans with HFpEF. However, the effect of sacubitril/valsartan on robust measures of MIF in humans is unknown. Demonstrating reductions in ECV with sacubitril/valsartan would clarify the mechanism of this approved medication. Given the borderline reduction in heart failure hospitalizations with sacubitril/valsartan and the heterogeneity of HFpEF pathophysiology, this result would suggest that neprilysin inhibition may particularly benefit HFpEF patients with greater MIF. The investigators propose a proof-of-concept clinical trial to evaluate the effect of neprilysin inhibition (sacubitril/valsartan vs valsartan alone) on cardiac MRI measures of fibrosis (principally ECV) and circulating protein levels.

Start Date27 Aug 2026

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

NCT06704633

/ RecruitingPhase 4IIT

Health Status After Switching Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers to Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania: An Interventional Study

Angiotensin-neprilysin inhibitors (ARNI) are beneficial in patients with heart failure with reduced ejection fraction. No study evaluating ARNI has been conducted in sub-Saharan Africa (except South Africa) yet, where heart failure is a major health problem. Before implementing ARNI in Tanzania, a study evaluating the benefit and safety of ARNI in Africans is needed. The aim of this interventional pre-post study is to evaluate the health status of symptomatic patients with heart failure with reduced ejection fraction who are under a chronic heart failure therapy, before and after switching angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) to ARNI. Participants will be recruited at the Heart and Lung Clinic of the St Francis Regional Referral Hospital in Ifakara in rural Tanzania during a study period of 30 months, including 10 months of follow-up. A total of 298 participants will be included. The investigators hypothesize that health status, expressed by the Kansas City Cardiomyopathy Questionnaire summary score and 6-minute walking test, will improve after switching from ACE-inhibitors or ARB to ARNI. In Tanzania, sacubitril/valsartan is registered under the name Uperio®.

Start Date30 Jun 2026

Sponsor / Collaborator

Swiss Tropical & Public Health Institute

[+1]

IRCT20251014067624N2

/ SuspendedPhase 2/3IIT

The effect of sacubitril/valsartan on blood pressure control and weight gain between hemodialysis sessions in patients with end-stage renal failure: A randomized controlled clinical trial study

Start Date22 Jun 2026

Sponsor / Collaborator

Tabriz University of Medical Sciences

100 Clinical Results associated with Sacubitril/Valsartan

100 Translational Medicine associated with Sacubitril/Valsartan

100 Patents (Medical) associated with Sacubitril/Valsartan

726

Literatures (Medical) associated with Sacubitril/Valsartan

01 Nov 2026·JOURNAL OF NUTRITIONAL BIOCHEMISTRY

Lactobacillus casei Zhang modulates hippocampal metabolism and cognition in T2DM rats: a microbiota-gut-brain axis study

Article

Author: Liu, Sijie ; Kang, Yan ; Liu, Huili ; Cheng, Linlin ; Lin, Fuchun ; Wang, Xuxia ; Cai, Yue ; Chen, Xi ; Guo, Haodong

The gut plays a pivotal role in metabolic disorders, providing a tractable target for type 2 diabetes mellitus (T2DM) prevention. Although Lactobacillus casei Zhang (LCZ) demonstrates cognitive benefits in T2DM, the mechanism by which LCZ modulates the gut microbiota to ameliorate cognition decline remains unelucidated. Therefore, we investigated the protective effects of LCZ against diabetic encephalopathy via the microbiota-gut-brain axis. Forty-two male Sprague-Dawley rats were randomly assigned to three groups (n=14/group): saline control (CON), T2DM group, and T2DM prevented with LCZ (T2DM+LCZ). Cognitive function was assessed by novel object recognition and Y-maze tests. Hippocampal metabolism was analyzed via ¹H NMR-based metabolomics. Gut microbiota composition was determined by 16S rRNA sequencing, and fecal short-chain fatty acid (SCFA) levels were quantified using targeted metabolomics. Compared with CON, T2DM rats exhibited significant increases in fasting blood glucose and insulin resistance, cognitive deficits, hippocampal metabolism disruption, elevated hippocampal inflammation, altered gut microbiota composition, and reduced SCFA. LCZ intervention (T2DM+LCZ group) effectively mitigated these T2DM-induced alterations, significantly lowering fasting blood glucose and insulin resistance, improving cognitive function, attenuating hippocampal inflammation, normalizing hippocampal metabolites, and restoring gut microbiota composition and SCFA levels. Crucially, no significant differences in most metrics were observed between the T2DM+LCZ and CON groups. Our findings demonstrate that LCZ alleviates T2DM-induced cognitive impairment by modulating the microbiota-gut-brain axis. Specifically, LCZ administration restores SCFA production and partially remodeled brain metabolism, highlighting its therapeutic promise for preventing diabetic encephalopathy.

01 Sep 2026·American Journal of Cardiovascular Drugs

Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study

Article

Author: Smith, Steven M ; Riaz, Munaza ; Park, Haesuk ; Dietrich, Eric A ; Winchester, David E

BACKGROUND:

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and sacubitril/valsartan (SAC/VAL), an angiotensin receptor-neprilysin inhibitor, are both US Food and Drug Administration-approved and guideline-recommended therapies for heart failure with reduced ejection fraction (HFrEF). While each has demonstrated significant reductions in cardiovascular morbidity and mortality, direct comparative evidence remains limited, particularly in relation to patients' diabetes status.

OBJECTIVE:

To compare the effectiveness of SAC/VAL versus SGLT2i in preventing HF-related and all-cause hospitalizations among patients with HFrEF, with or without diabetes, using real-world data from the MarketScan^® Research databases.

METHODS:

This new-user, active-comparator cohort study using MarketScan^® Commercial and Medicare databases (2019-2023) identified patients with HFrEF by using International Classification of Diseases codes. Patients who initiated SAC/VAL or SGLT2i treatment were included, with the index date defined as the first prescription fill. Continuous health plan enrollment ≥ 6 months prior to HFrEF diagnosis through the index date was required. To balance baseline characteristics between groups, we applied stabilized inverse probability of treatment weighting (IPTW). Cox proportional hazards models compared risks of HF-related and all-cause hospitalizations in cohort analyses defined by diabetes status, diagnosis, and antidiabetic medications.

RESULTS:

After IPTW, the study included 7406 patients initiating SAC/VAL and 5101 patients initiating SGLT2i. Among patients with diabetes, there were no significant differences in the risks of HF-related hospitalization (adjusted hazard ratio [aHR] 1.13, 95% confidence interval [CI] 0.98-1.30) or all-cause hospitalization (aHR 0.99, 95% CI 0.90-1.09) between medication groups. In contrast, among patients without diabetes, initiation of SAC/VAL was associated with significantly lower risks of HF-related hospitalization (aHR 0.65, 95% CI 0.56-0.76) and all-cause hospitalization (aHR 0.69, 95% CI 0.62-0.77).

CONCLUSIONS:

In a real-world cohort of patients with HFrEF and without diabetes, but not those with diabetes, SAC/VAL initiation was associated with reduced risks of HF-related and all-cause hospitalizations compared with SGLT2i initiation. These findings provide supportive evidence that may inform clinicians when selecting therapy for patients with HFrEF.

01 Aug 2026·INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Sacubitril/Valsartan as a Cardiac Radioprotector

Article

Author: Kerr, Brianna N ; Comer, Siobhan ; Harbinson, Mark T ; Butterworth, Karl T ; Watson, Chris J ; Grieve, David J ; Seelan, Arvin Suguna ; Ghita-Pettigrew, Mihaela ; Karuna, Narainrit ; Brown, Kathryn H ; Herron, Brian ; Edgar, Kevin S ; Greystoke, Alastair ; Walls, Gerard M ; Faivre-Finn, Corinne

PURPOSE:

The role of the natriuretic peptides in radiation heart injury (RHI) has not been thoroughly examined. Pharmacologic modulation of the natriuretic peptide system with sacubitril/valsartan (sac/val) has led to improvements in heart failure therapy, and preliminary data suggest that RHI is associated with decreased atrial natriuretic peptide (ANP). In this study, we assessed sac/val as a radioprotector in a partial-heart irradiation mouse model and explored preliminary trends in patients receiving thoracic irradiation.

METHODS AND MATERIALS:

Female 8-10-week-old C57BL/6J mice were randomly assigned to receive sham irradiation, with or without sac/val, or irradiation with or without sac/val. The superior two-thirds of the heart was exposed to 20 Gy of x-rays using a small animal radiation research platform. Cardiac function was assessed at 10-week intervals over 30 weeks by transthoracic echocardiography and electrocardiography. Plasma levels of ANP were analyzed at 30 weeks. Small retrospective clinical series were undertaken in patients undergoing thoracic radiation therapy, to assess ANP dynamics and sac/val safety.

RESULTS:

At 30 weeks, irradiated mice that received sac/val exhibited a marked improvement in structural remodeling, systolic longitudinal strain, diastolic function, and electrophysiological parameters, compared with irradiated animals that did not receive sac/val. Functional sparing with sac/val was detectable as early as 10 weeks postirradiation by global longitudinal strain. Animals and patients tolerated the combination of sac/val with radiation without additional adverse effects. NT-proANP levels generally decreased among patients during thoracic radiation therapy and posttreatment NT-proANP changes were dose dependent. There was no effect on tolerability or efficacy of (chemo)radiation for patients on sac/val concurrently for heart failure.

CONCLUSIONS:

Sac/val attenuated structural and functional aspects of RHI and was well tolerated in animals when given with radiation. Clinical data suggest that ANP changes dynamically during radiation therapy and that sac/val is safe to take concurrently. Further investigation of sac/val as a cardiac radioprotector is warranted.

330

News (Medical) associated with Sacubitril/Valsartan

19 Aug 2026

·www.biospace.com

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio ® (inclisiran) vs. bempedoic acid in achieving LDL-C goals New AZALEA-TIMI 71 analyses will further characterize the bleeding pro abelacimab in patients with atrial fibrillation, including recurrent bleeding events Lp(a)CCELERATE, in partnership with European Atherosclerosis Society (EAS), will explore strategies to help advance guideline-recommended Lp(a) testing in clinical practice Basel, August 19, 2026 – Novartis will present data from 10 abstracts across its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress, reinforcing its leadership in addressing cardiovascular risk. “The data we are presenting at this year’s ESC Congress underscore our commitment to advancing cardiovascular science for patients who remain at risk despite current treatment,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development, Novartis. “From foundational medicines Leqvio and Entresto to promising investigational therapies, our portfolio reflects our focus on addressing persistent challenges in cardiovascular care.” Key abstracts accepted by ESC include: Medicine/Disease Abstract Title Presentation Details Leqvio ® Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial Tripoli (Hall B1) Late-Breaking Oral Presentation August 31, 08:15-08:30 CEST Leqvio ® An inclisiran-based treatment strategy reduces the need for therapy escalation to achieve low-density lipoprotein cholesterol goals: Exploratory findings from the VICTORION-Difference trial Exchange Circle 3 (Research Gateway – Hall A1) ePoster August 29, 09:15-10:00 CEST Abelacimab Effect of abelacimab vs. rivaroxaban on total bleeding events in patients with atrial fibrillation: an analysis from AZALEA-TIMI71 Science Box 2 (Research Gateway – Hall A1) Oral Presentation August 29, 09:30-10:30 CEST Lipoprotein (a) [Lp(a)] Mobilizing core and country-tailored implementation strategies to accelerate Lipoprotein(a) testing across Europe: findings from the Lp(a)CCELERATE contextual analysis Exchange Circle 6 (Research Gateway – Hall A1) ePoster August 29, 16:15-17:00 CEST Entresto ® Effects of sacubitril/valsartan versus enalapril on NT-proBNP and hs-troponin T in patients with heart failure due to Chagas disease: insights from the PARACHUTE-HF trial Station 5 (Research Gateway – Hall A1) ePoster August 31, 09:15-10:00 CEST Pacibekitug TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk Munich (Main Auditorium-Hall B3) Hot Line August 29, 08:45-09:00 CEST About Novartis in Cardiovascular Disease At Novartis, we're redefining cardiovascular care, shifting toward earlier action, expanding how we understand and treat cardiovascular disease, and pushing the boundaries of what's possible so more people can live longer, healthier lives. Building on our 40-year legacy, we're committed to shaping what's next in cardiovascular care through bold science and a diverse, industry-leading pipeline. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . # # # Novartis Media Relations E-mail: media.relations@novartis.com Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

AHAPhase 3Clinical Result

21 Jul 2026

·www.fiercepharma.com

Novartis CEO brushes off oral PCSK9 competition as Leqvio drives Q2 growth

Novartis' CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s Lipfendra , doubling down on the long-term potential of his company's injectable cholesterol drug, Leqvio. Speaking on the company’s Q2 earnings call, Novartis CEO Vas Narasimhan brushed off fears that daily pills could stall Leqvio. As Novartis moves past key patent expirations to deliver a return to top-line growth—partly thanks to strong performance from Leqvio—Narasimhan argued that Leqvio’s twice-yearly dosing offers a unique opportunity. “Even with orals launching, our opportunity remains for driving strong growth in the segment that wants infrequently administered, physician-administered medicines for lipid lowering in the United States, and we see this as an attractive and growing segment that supports our peak sales potential in the U.S. and beyond,” Narasimhan said. Novartis has pegged Leqvio peak sales at above $4 billion, based on the fact that many of the more than 70 million U.S. patients with elevated LDL cholesterol were not able to reach their lipid-lowering targets with older treatments. Initially struggling with a slow launch as doctors got accustomed to the “buy-and-bill” reimbursement model, Leqvio reached blockbuster status in 2025 with $1.2 billion in sales. In this year's second quarter, the small interfering RNA therapy grew sales by 59% at constant currencies, reaching $480 million, landing 5% above analysts’ expectations. In the U.S., Narasimhan highlighted monthly total prescription growth of 49%, as Leqvio “outpaced the advanced lipid-lowering market.” With Medicare Part B use, which the CEO said represents Leqvio’s most important segment, Novartis currently keeps a 23.3% share, up 3.6% year to date. With Lipfendra’s launch, the buy-and-bill pathway for physician-administered drugs now works in Leqvio’s favor, insulating the Novartis med from the potentially brutal price battle between orals and self-injected antibody therapies, Narasimhan noted. Outside the U.S., Narasimhan predicts Leqvio could become Novartis’ largest medicine ever in China, even ahead of the company’s megablockbuster heart failure treatment Entresto. Following its recent inclusion in China’s National Reimbursement Drug List, Leqvio has now doubled its market share, with strong performance in both the hospital setting and other market segments, according to Narasimhan. “We think there’s an opportunity in cardiovascular, hypertension and [cardiovascular] risk reduction for our follow-on siRNAs in China, where there seems to be a high demand for infrequently administered therapies with very clean safety profiles,” Narasimhan said. To potentially further bolster Leqvio’s clinical profile, Novartis is on track to report data from two cardiovascular outcomes studies in 2027. Leqvio is among several new medicines that drove Novartis’ Q2 sales to 1% growth at constant exchange rates, a surprisingly strong showing coming off of a 5% decline in Q1. Entresto, which was once Novartis’ top-selling drug, continued to see significant sales erosion thanks to its U.S. loss of exclusivity. Sales from the drug plummeted 51% in Q2, tumbling below $1.2 billion and missing Wall Street consensus estimates by 9%. In contrast, immunotherapy asset Cosentyx chalked up a 10% increase at an unchanged exchange rate, reaching $1.8 billion. Breast cancer drug Kisqali brought in $1.7 billion in sales in Q2, representing 43% year-over-year growth, and Kesimpta’s $1.4 billion in sales marked a 32% jump. Despite a 5% overall groupwide top-line beat versus consensus, Novartis maintained its full-year sales guidance. As CFO Mukul Mehta noted on Tuesday’s call, the company’s Q2 revenue benefited 1 percentage point from some “one-time phasing items, which will reverse in the second half.”

Drug ApprovalIPO

21 Jul 2026

·firstwordpharma.com

Novartis returns to growth on second-quarter performance of key drugs

Despite deepening generic headwinds, particularly to Entresto, Novartis on Tuesday posted a 3% uptick in overall sales for the second quarter to $14.4 billion, marking a return to growth from the first three-month period of the year when revenue slipped 1%."Novartis delivered a solid second quarter, returning to sales growth driven by continued momentum from Kisqali, Kesimpta, Scemblix and Pluvicto," said CEO Vas Narasimhan, adding "we are encouraged by the early trajectory of our recent launches, Rhapsido…and Itvisma."Generic competition pushed sales of Entresto down 50% in the second quarter to $1.2 billion, while Promacta/Revolade and Tasigna were also affected, falling 64% and 57%, respectively, to $179 million and $142 million. In February, Novartis warned that it faces the largest patent cliff in its history, with a $4-billion hit to sales expected in 2026.Despite this, the company still forecasts that revenue will grow this year in the low-single digits on a constant currency basis, spearheaded by Kisqali. In the second quarter, sales of the breast cancer drug jumped 44% to $1.7 billion — other bright spots in the three-month period included Kesimpta (+32% to $1.4 billion), Pluvicto (+43% to $651 million) and Scemblix (+89% to $562 million). For new launches, Novartis said that Rhapsido continued "to show strong early uptake in the US," boosted by increasing coverage, with sales of the chronic spontaneous urticaria treatment reaching $64 million.Commenting on the results, which also saw net income fall 19% to $3.3 billion, Vontobel analyst Stefan Schneider said "we are surprised that the good second quarter does not trigger a guidance upgrade."For related analysis, see Spotlight On: Three things to watch at Novartis.

Biosimilar

100 Deals associated with Sacubitril/Valsartan

External Link

KEGG	Wiki	ATC	Drug Bank
D10226	-	C09DX04	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	China	Novartis Pharma Schweiz AG	24 May 2021
Hypertension	Japan	Novartis Pharma KK	29 Jun 2020
Left ventricular systolic dysfunction	United States	Novartis Pharmaceuticals Corp.	01 Oct 2019
Reduced ejection fraction co-occurrent and due to chronic heart failure	European Union	Novartis Europharm Ltd.	19 Nov 2015
Reduced ejection fraction co-occurrent and due to chronic heart failure	Iceland	Novartis Europharm Ltd.	19 Nov 2015
Reduced ejection fraction co-occurrent and due to chronic heart failure	Liechtenstein	Novartis Europharm Ltd.	19 Nov 2015
Reduced ejection fraction co-occurrent and due to chronic heart failure	Norway	Novartis Europharm Ltd.	19 Nov 2015
Heart Failure	Switzerland	Novartis AG	17 Sep 2015
Chronic heart failure	United States	Novartis Pharmaceuticals Corp.	07 Jul 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Postmyocardial infarction syndrome	Phase 3	-	Novartis Pharmaceuticals Corp.	26 May 2021
Erectile Dysfunction	Phase 3	Germany	Novartis Pharmaceuticals Canada, Inc.	16 Apr 2019
Heart Failure, Systolic	Phase 3	Germany	Novartis Pharmaceuticals Canada, Inc.	16 Apr 2019
Acute myocardial infarction	Phase 3	United States	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	China	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	Argentina	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	Australia	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	Austria	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	Belgium	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	Brazil	Novartis Pharmaceuticals Corp.	09 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04113109 (CTgov)	Phase 4	Heart Failure	46	placebo+valsartan+sacubitril (Placebo)	xglddxbudc(txzbnzvpgv) = xixvhskoeq rewafkfzvf (doqizrxrkw, 9.47) View more	-	11 Aug 2026
				Icatibant (Icatibant)	xglddxbudc(txzbnzvpgv) = drscdiyctv rewafkfzvf (doqizrxrkw, 8.37) View more
NCT04023227 (PARACHUTE-HF, CTgov)	Phase 4	Chagas Cardiomyopathy \| Heart Failure	922	Sacubitril/valsartan (Sacubitril/Valsartan)	azuybefthg = ikuxozoyns gpiqikbtzn (gttgcvvqxc, cucrkhfxqy - yalguzllnq) View more	-	11 May 2026
				enalapril (Enalapril)	azuybefthg = vtqmcrpvor gpiqikbtzn (gttgcvvqxc, wymmqpxkvk - hfmsfdkpnx) View more
ChiCTR2100051742 (FUNCTION, Pubmed \| Cardiovasc Drugs Ther)	Early Phase 1	Atrial Fibrillation	240	Sacubitril/Valsartan	yvwhwqoleq(vzneandtng): adjusted mean difference = -1.9 (95.0% CI, -3.2 to -0.5), P-Value = 0.02 View more	Positive	01 Apr 2026
				Placebo
NCT05164653 (PREMIER, Pubmed \| J Card Fail)	Phase 4	Heart Failure	376	Sacubitril/Valsartan with uptitration	oqgvigntom(ozmsegmpsa) = jdkoqnuvgg ytnnupukip (hsbhkzfhsy )	Positive	01 Mar 2026
				Sacubitril/Valsartan without uptitration	oqgvigntom(ozmsegmpsa) = whtbvcmhzn ytnnupukip (hsbhkzfhsy )
NCT04103554 (ENVAD-HF, Pubmed \| J Card Fail)	Phase 2	Heart Failure	60	Sacubitril/valsartan	hdzuxmqgub(cjghbcazpy) = xwaybrhrqm eundxvsaex (pbdagestmg, 1595.0)	Positive	01 Feb 2026
				Standard of Care (SOC)	hdzuxmqgub(cjghbcazpy) = jghmzzdyrk eundxvsaex (pbdagestmg, 3543.0)
NCT04023227 (Pubmed \| JAMA)	Phase 4	Chagas Disease	922	Sacubitril/Valsartan	wfhfmgtcgy(rijyfygtcz) = mxqqerirbf zfklvezaed (yblemxiujn ) View more	Negative	06 Jan 2026
				Enalapril	wfhfmgtcgy(rijyfygtcz) = ldbaejwfoq zfklvezaed (yblemxiujn ) View more
NCT04023227 (Pubmed \| JAMA)	Phase 4	Chagas Disease	922	Sacubitril/Valsartan	ixaufjfxme(abfediumoz) = xskotmlkle doqgioqguj (rwaoihaguj ) View more	Negative	03 Dec 2025
				Enalapril	ixaufjfxme(abfediumoz) = dudmpajjdc doqgioqguj (rwaoihaguj ) View more
NCT01920711 \| NCT01035255 (PARAGON-HF, Pubmed \| Eur Heart J Cardiovasc Pharmacother)	Phase 3	Heart failure with normal ejection fraction \| Heart failure with reduced ejection fraction	12,974	Sacubitril/valsartan	nvxygumupd(oyvtoywhtm): OR = 1.16 (95.0% CI, 1.08 - 1.24) View more	Positive	04 Nov 2025
				Enalapril or valsartan
NCT04853758 (ANSWER-HF, Pubmed \| J Am Coll Cardiol)	Phase 4	Chagas Disease	190	Sacubitril-valsartan	bnrpfhzhee(ytfixygepb) = sevyatclmj nepayopfcr (yrbuopttls )	Positive	01 Nov 2025
				Enalapril	bnrpfhzhee(ytfixygepb) = bwazxwfdnt nepayopfcr (yrbuopttls )
NCT03988634 (PARAGLIDE-HF, Pubmed \| Am Heart J)	Phase 3	Heart Failure NT-proBNP \| LVEF	847	Sacubitril/valsartan	pmyddefjik(jpumxzflwv): rate ratio = 0.6 (95% CI, 0.37 - 0.99), P-Value = 0.046 View more	Positive	01 Nov 2025
				Valsartan

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis